Sign In
Buy VRTX
$428.34
+3.25 (+0.765%)
At Close: Jun 03, 2026
Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst
11:13am, Monday, 23'rd Dec 2024
Vertex Pharmaceuticals Inc VRTX last week announced that the Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR) had met its primary endpoint.
Lost Money on Vertex Pharmaceuticals Incorporated (VRTX)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
07:45am, Monday, 23'rd Dec 2024
NEW YORK, NY / ACCESSWIRE / December 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRT
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
04:30am, Sunday, 22'nd Dec 2024
Vertex Pharmaceuticals (VRTX 0.16%) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global leader in c
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
06:48am, Saturday, 21'st Dec 2024
Santa Claus will soon be on his way delivering presents to kids around the world. But could the jolly gift-giver bring something for investors, too?
My Top 10 Stocks to Buy for 2025
04:05am, Saturday, 21'st Dec 2024
It's that time of year again. I'm not referring to buying gifts and preparing holiday meals -- although that may be part of your agenda too.
Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock
06:16pm, Friday, 20'th Dec 2024
The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late Friday. The post Vertex Wins An Early Approval; Why It Might Not Move Vertex
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment
04:01pm, Friday, 20'th Dec 2024
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and progressive genetic disease, the company said on Friday, expanding its dominance in
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
03:46pm, Friday, 20'th Dec 2024
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaf
NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRT
NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRT
VRTX Down as Non-Opioid Drug Shows Similar Pain Reduction as Placebo
12:16pm, Friday, 20'th Dec 2024
Vertex announces data from a phase II study evaluating its NaV1.8 pain signal inhibitor, suzetrigine, for treating painful lumbosacral radiculopathy. Shares down.
Cramer's Mad Dash: Vertex Pharmaceuticals
10:12am, Friday, 20'th Dec 2024
CNBC's Jim Cramer delivers his daily Mad Dash.
BOSTON, MA / ACCESSWIRE / December 20, 2024 / Block & Leviton is investigating Vertex Pharmaceuticals Inc. (Nasdaq:VRTX) for potential securities law violations. Investors who have lost money in their
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
08:00am, Friday, 20'th Dec 2024
Vertex stock was floundering even before Thursday when the company's non-opioid pain drug underperformed expectations in a midstage study. The post Is Vertex Stock A Sell After Pain Drug Whiffs In Mid
